Key clinical point:
Major finding: The hazard ratio for GVHD-free and relapse-free survival was 0.72 for those receiving cyclophosphamide, compared with controls (P = .04).
Study details: Randomized, controlled trial of 497 patients receiving one of three intervention arm posttransplant regimens for GVHD prophylaxis, or a control regimen of tacrolimus and methotrexate.
Disclosures: Dr. Bolaños-Meade reported serving on the data safety monitoring board of Incyte.
Source: Bolaños-Meade J et al. 2018 BMT Tandem Meetings, Abstract LB1.
Bolaños-Meade J et al. 2018 BMT Tandem Meetings, Abstract LB1.
This Week's Must Reads
Must Reads in Cellular Therapy
Haplo-HCT shows viability in DLBCL, Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9